A clinical trial to evaluate a vaccine designed to protect against the new coronavirus will begin on Monday, the Associated Press reported, citing an unnamed US government official.
The first participant in the trial, which is being funded by the National Institutes of Health and taking place at the Kaiser Permanente Washington Health Research Institute in Seattle, will receive the experimental vaccine on Monday, the AP reported
It would take a year to 18 months to fully validate any potential vaccine, the AP added, citing public health officials.
Testing will begin with 45 young, healthy volunteers with different doses of shots co-developed by NIH and Moderna Inc. There’s no chance participants could get infected from the shots, because they don’t contain the virus itself. The goal is purely to check that the vaccines show no worrisome side effects, setting the stage for larger tests, the news agency said.
Dozens of research groups around the world are racing to create a vaccine as Covid-19 cases continue to grow.
Importantly, they’re pursuing different types of vaccines — shots developed from new technologies that not only are faster to produce than traditional inoculations but might prove more potent.
Some researchers even aim for temporary vaccines, such as shots that might guard people’s health a month or two at a time while longer-lasting protection is developed.
The United States and Germany are vying to produce an exclusive vaccine which is being developed in a German laboratory, Die Welt daily reported Saturday.
According to the paper, US President Donald Trump is trying to poach German scientists working on an experimental vaccine against a global health threat that has now killed some 5,500 people with a view to having an exclusive licence rolled out in the United States.
The German government promised Sunday to defend itself against alleged attempts by Trump to buy exclusive rights to a German company's research into a vaccine against the coronavirus.



